SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Drug Delivery System

PUBLISHER: Roots Analysis | PRODUCT CODE: 2161674

Cover Image

PUBLISHER: Roots Analysis | PRODUCT CODE: 2161674

Lipid Nanoparticle Manufacturing Market - Trends and Forecast Till 2035

PUBLISHED:
PAGES: 297 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4799
PDF & Excel & Summary Pack (Business Unit License)
USD 7999
PDF & Excel & Summary Pack (Enterprise License)
USD 17999

Add to Cart

Description

Table of Contents

List of Tables

LIPID NANOPARTICLE MANUFACTURING MARKET: OVERVIEW

The global lipid nanoparticle manufacturing market is estimated to grow from USD 0.38 billion in the current year to USD 2.53 billion by 2035, at a CAGR of 23.4% during the forecast period, till 2035. Growth is being propelled by the fast-expanding pipeline of mRNA-based vaccines and therapeutics, rising adoption of lipid nanoparticle (LNP) delivery systems in oncology and rare disease programs, and continued investment in GMP-grade formulation and fill-finish capacity by contract development and manufacturing organizations (CDMOs) worldwide.

Lipid Nanoparticle Manufacturing Market - IMG1

Lipid Nanoparticle Manufacturing Market: Growth and Trends

Lipid nanoparticles are nanoscale, lipid-based delivery vehicles engineered to encapsulate and protect therapeutic payloads. These nanoparticles can encapsulate payloads ranging from messenger RNA (mRNA) and small interfering RNA (siRNA) to small molecules and peptide or protein-based drugs. By shielding sensitive cargo from enzymatic degradation and improving cellular uptake, biodistribution, and bioavailability, LNPs have become a foundational enabling technology for next-generation nucleic acid medicines, prophylactic vaccines, oncology candidates, and rare disease therapeutics.

The clinical and commercial validation of LNP-enabled mRNA vaccines during the COVID-19 pandemic transformed lipid nanoparticles from a niche delivery format into a mainstream pharmaceutical manufacturing discipline. Momentum has continued to build as newer LNP-based products reach approval and later-stage development beyond infectious disease, reinforcing the platform's versatility across therapeutic areas and reigniting demand for specialized formulation science, custom lipid supply, and scalable GMP manufacturing.

The manufacturing of lipid nanoparticle (LNP)-based products is technically challenging, as their performance depends on precise control over lipid composition, particle size, polydispersity, encapsulation efficiency, sterility, and long-term stability. Even small deviations in mixing conditions, raw material purity, or process parameters can materially affect product quality and clinical performance. In response, manufacturers are increasingly turning to microfluidic mixing systems, automated and closed formulation platforms, continuous processing methods, and advanced particle-characterization tools to tighten batch-to-batch consistency and to support the transition from bench-scale development to commercial-scale GMP output.

Looking ahead, the lipid nanoparticle manufacturing market is expected to benefit from the expanding pipeline of RNA-based therapeutics and a maturing supplier base for specialty and ionizable lipids. Demand is also rising among pharmaceutical and biotechnology companies to outsource formulation, analytical characterization, and sterile fill-finish activities to experienced CDMOs rather than build these capabilities in-house.

Growth Drivers: Strategic Enablers of Market Expansion

Expansion of the lipid nanoparticle manufacturing market is being driven first and foremost by the accelerating pipeline of mRNA vaccines and RNA-based therapeutics. Presently, nearly 244 mRNA vaccine and therapeutic candidates are under the development stage, including 102 oncology-focused candidates, with 12 programs already in late-stage trials., with a meaningful share of these programs already advancing into late-stage clinical trials. As more of these candidates progress toward regulatory filing and commercial launch, sponsors require scalable LNP formulation, encapsulation, analytical testing, and validated GMP manufacturing support, creating durable, multi-year demand for specialized capacity.

In addition, the rising advancements and availability of advanced lipid materials are supporting market growth. LNP performance depends heavily on the quality and design of ionizable lipids, helper lipids, cholesterol, and PEGylated lipids used in the formulation. Specialty lipid suppliers are broadening their portfolios and entering strategic collaborations to support increasingly complex payloads, including mRNA, peptide, and protein-based therapeutics, which in turn is improving delivery efficiency, tissue targeting, and manufacturability across the industry.

Additionally, growing biopharma interest in personalized and n-of-few RNA-LNP therapies is creating demand for more flexible manufacturing models. Continued investment by major vaccine manufacturers is also expanding mRNA production capacity. Meanwhile, flexible and potentially point-of-care LNP preparation models could eventually reduce reliance on centralized, high-cost manufacturing infrastructure.

Market Challenges: Critical Barriers Impeding Progress

Despite an encouraging growth trajectory, the lipid nanoparticle manufacturing market faces several structural challenges that may hinder the market growth. Scale-up from laboratory-scale batches to commercial GMP production remains technically demanding, requiring precise control over particle size distribution, morphology, lipid purity, and encapsulation efficiency, along with robust in-process controls and validated analytical methods to ensure batch-to-batch consistency.

Formulation optimization is another significant challenge for the market players. Many LNP platforms still require extensive tailoring of lipid composition, particle properties, and payload-specific parameters to achieve reliable delivery beyond well-established routes and tissue targets, adding development complexity for oncology, rare disease, gene-editing, and protein or peptide delivery programs. Manufacturers must also contend with cold-chain logistics requirements, raw material availability constraints for specialty lipids, and evolving regulatory expectations around characterization and comparability, all of which can slow time-to-clinic and add cost for smaller developers and emerging biotech sponsors.

Lipid Nanoparticle Manufacturing Market: Key Segment Insights

Solid Lipid Nanoparticles Continue to Lead the Market

Based on our assessment, solid lipid nanoparticles hold the largest share of the lipid nanoparticle manufacturing market by type and are expected to maintain dominance during the forecast period. This is attributable to their well-characterized formulation profiles, established and standardized manufacturing protocols, good physical stability, and broad track record across nucleic acid delivery, vaccine development, and pharmaceutical research.

On the other hand, nanostructured lipid carriers are gaining traction for their improved drug-loading capacity and lower risk of payload expulsion during storage, positioning them as the faster-growing sub-segment as developers pursue more complex RNA therapeutics.

Nucleic Acid Payloads Hold the Largest Molecule Type Share

Nucleic acids payloads account for the largest share of the lipid nanoparticle manufacturing market by molecule type. This high share is largely due to the strong clinical and commercial validation of LNPs as delivery vehicles for RNA vaccines and RNA interference therapeutics, where the lipid shell protects nucleic acid payloads from enzymatic degradation and enhances intracellular uptake. Small-molecule payloads represent a smaller but faster-growing segment, as developers increasingly evaluate LNP formulation to improve the solubility, stability, and controlled release of poorly water-soluble compounds in oncology and inflammatory disease programs.

North America Maintains Regional Market Leadership

North America is projected to remain the largest regional market for lipid nanoparticle manufacturing through 2035. The region's leadership in lipid nanoparticle manufacturing is supported by a strong RNA therapeutics pipeline, established vaccine manufacturers, mature GMP facilities, and a well-developed CDMO ecosystem. Ongoing investments by leading mRNA manufacturers are further expanding domestic LNP formulation and production capacity, strengthening supply security and reducing reliance on external manufacturing partners.

Asia-Pacific Emerges as the Fastest-Growing Regional Market

The Asia-Pacific lipid nanoparticle manufacturing market is expected to register the highest CAGR during the forecast period. Growth is being fueled by rising investment in mRNA vaccine infrastructure, expanding domestic biomanufacturing capacity, pandemic-preparedness initiatives, and growing interest in locally developed RNA-based therapies across China, Japan, South Korea, India, and Australia.

Pharmaceutical and Biotechnology Companies Lead the End-User Segment

Pharmaceutical and biotechnology companies hold the largest share of the market. Their dominant position is driven by active involvement in RNA therapeutics, mRNA vaccines, cancer vaccines, and gene-modulation programs that require specialized LNP formulation development, GMP-grade production, analytical characterization, and stability testing across the clinical and commercial life cycle. This segment is also expected to grow fastest through 2035 as more RNA-based and LNP-enabled candidates progress from discovery into clinical and commercial-stage development.

Example Players in the Lipid Nanoparticle Manufacturing Market

  • Acuitas Therapeutics
  • Ascendia Pharmaceuticals
  • Avanti Polar Lipids
  • BIOVECTRA
  • CordenPharma
  • Creative Biolabs
  • Curapath
  • Curia
  • Emergent Biosolutions
  • EUROAPI
  • Evonik
  • Formumax Scientific
  • Fresinius Kabi
  • Fujifilm
  • Integrated Nanotherapeutics
  • leon-nanodrugs
  • Matinas BioPharma
  • Merck
  • Pantherna Therapeutics
  • Precision NanoSystems
  • TLC Biosciences

Expert Interview and Industry Insights

The opinions and insights presented in this study have been informed by structured discussions with multiple industry stakeholders active across the lipid nanoparticle manufacturing value chain. The research features detailed interview transcripts with stakeholders including:

  • Founder and Chief Executive Officer, Small Company, Netherlands
  • Former Director, Process Development, Chemistry and Former Acting Manager, Biotech Process Development, Large Company, Canada
  • Formulation Scientist, Small Company, US

In addition, the market report includes transcripts of the following other third-party discussions:

  • Chief Executive Officer; Chief Operating Officer, Mid-sized Company, US
  • Chief Executive Officer, Mid-sized Company, Canada
  • Chief Executive Officer, Mid-sized Company, Taiwan
  • Founder, Chair and Chief Executive Officer, Small Company, China
  • Chief Executive Officer, Mid-sized Company, China
  • Chief Executive Officer; Commercial Officer, Small Company, US
  • Board Chair and Co-Founder; Chief Scientific Officer and Co-Founder, Small Company, Canada
  • Executive Director and Head of Next Generation Drug Delivery, Very Large Company, Germany
  • Patent Prosecution Partner; IP Litigation Partner, Large Company, US
  • Lipid Nanoparticle Consultant, Small Company, US

LIPID NANOPARTICLE MANUFACTURING MARKET: RESEARCH COVERAGE

  • Market Sizing and Opportunity Analysis: An in-depth analysis of the lipid nanoparticle manufacturing market, segmented by [A] type of lipid nanoparticle, [B] type of molecule delivered, [C] company size, [D] therapeutic area, [E] end-user and [F] key geographical regions.
  • LNP Manufacturing Landscape: A detailed assessment of the current lipid nanoparticle manufacturing landscape, capturing information on formulation capabilities, integrated technologies, development stage supported, and year of establishment, company size, and location of headquarters of active manufacturers.
  • Company Profiles: In-depth profiles of prominent players engaged in lipid nanoparticle manufacturing, featuring year of establishment, headquarters, company size, service portfolio, and recent strategic initiatives.
  • Partnerships and Collaborations: A detailed partnerships and collaborations analysis covering details on parameters such as year of partnership, type of partnership, regional analysis.
  • Company Competitiveness Analysis: A detailed assessment of companies in the lipid nanoparticle domain featuring information on company strength and manufacturers strength.
  • Market Impact Analysis: An analysis of the drivers, restraints, opportunities, and challenges expected to influence the evolution of the lipid nanoparticle manufacturing market through the forecast period.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How big is the lipid nanoparticle manufacturing market, and what is its projected growth through 2035?
  • Which type of lipid nanoparticle and molecule class currently leads the market, and which is likely to grow fastest?
  • Which region dominates the lipid nanoparticle manufacturing market, and which region offers the highest growth potential?
  • Who are the leading companies operating in the lipid nanoparticle manufacturing space?
  • What are the primary growth drivers and restraints shaping this market?
  • What key trends are influencing the evolution of lipid nanoparticle manufacturing technology and capacity?
  • How is current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections for the overall lipid nanoparticle manufacturing market and its constituent sub-segments, valuable to both established market leaders and emerging entrants.
  • It offers stakeholders a well-rounded overview of the market, including key drivers, barriers, opportunities, and challenges, empowering data-driven decision-making.
  • It helps businesses identify future opportunities across the LNP manufacturing value chain and assess whether those opportunities are worth pursuing.
  • It supports demand identification by clarifying the needs, preferences, and behavior of the target customer base, enabling more effective service and capability positioning.
  • It equips new entrants with the requisite market intelligence to build informed capacity-investment and go-to-market strategies.
  • It enables more effective communication with prospective partners and clients, and supports the development of stronger business relationships across the industry.

ADDITIONAL BENEFITS

  • Complimentary Excel data packs for all analytical modules in the report
  • 15% free content customization
  • Detailed report walkthrough session with the research team
  • Free updated report if the current edition is 6-12 months old or older
Show more
Product Code: RA100461

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Market Segmentations
  • 1.4. Key Questions Answered
  • 1.5. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
    • 2.2.3. Comparative Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databases and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Providers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases
  • 2.5. Robust Quality Control

3. MARKET DYNAMICS

  • 3.1. Chapter Overview
  • 3.2. Forecast Methodology
    • 3.2.1. Top-down Approach
    • 3.2.2. Bottom-up Approach
    • 3.2.3. Hybrid Approach
  • 3.3. Market Assessment Framework
    • 3.3.1. Total Addressable Market (TAM)
    • 3.3.2. Serviceable Addressable Market (SAM)
    • 3.3.3. Serviceable Obtainable Market (SOM)
    • 3.3.4. Currently Acquired Market (CAM)
  • 3.4. Forecasting Tools and Techniques
    • 3.4.1. Qualitative Forecasting
    • 3.4.2. Correlation
    • 3.4.3. Regression
    • 3.4.4. Extrapolation
    • 3.4.5. Convergence
    • 3.4.6. Sensitivity Analysis
    • 3.4.7. Scenario Planning
    • 3.4.8. Data Visualization
    • 3.4.9. Time Series Analysis
    • 3.4.10. Forecast Error Analysis
  • 3.5. Key Considerations
    • 3.5.1. Demographics
    • 3.5.2. Government Regulations
    • 3.5.3. Reimbursement Scenarios
    • 3.5.4. Market Access
    • 3.5.5. Supply Chain
    • 3.5.6. Industry Consolidation
    • 3.5.7. Pandemic / Unforeseen Disruptions Impact
  • 3.6. Limitations

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Overview of Lipids
  • 5.3. Introduction to Lipid Nanoparticles
    • 5.3.1. Types of Lipid Nanoparticles
      • 5.3.1.1. Solid Lipid Nanoparticles
      • 5.3.1.2. Nanostructured Lipid Carriers
    • 5.3.2. Advantages of Lipid Nanoparticles
    • 5.3.3. Applications of Lipid Nanoparticles in Pharmaceutical Industry
      • 5.3.3.1. Cancer Treatment
      • 5.3.3.2. Gene Therapy
      • 5.3.3.3. Vaccine Development
      • 5.3.3.4. Medical Imaging / Diagnostics
      • 5.3.3.5. Additional Applications
  • 5.4. Challenges Associated with Lipid Nanoparticle Manufacturing
  • 5.5. Need for Outsourcing Lipid Nanoparticle Manufacturing
  • 5.6. Concluding Remarks

6. LIPID NANOPARTICLES: SERVICE PROVIDERS LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Lipid Nanoparticle Manufacturing: List of Service Providers
    • 6.2.1. Analysis by Year of Establishment
    • 6.2.2. Analysis by Company Size
    • 6.2.3. Analysis by Location of Headquarters
    • 6.2.4. Analysis by Company Size and Location of Headquarters
    • 6.2.5. Analysis by Location of Lipid Nanoparticle Manufacturing Facility
    • 6.2.6. Analysis by Scale of Operation
    • 6.2.7. Analysis by Type of Molecule Delivered
    • 6.2.8. Analysis by Therapeutic Area
    • 6.2.9. Analysis by Type of Additional Services Offered

7. LIPID NANOPARTICLES: TECHNOLOGY LANDSCAPE

  • 7.1. Chapter Overview
  • 7.2. Lipid Nanoparticle: Technology Landscape
    • 7.2.1. Analysis by Type of Formulation Method
    • 7.2.2. Analysis by Type of Molecule Delivered
    • 7.2.3. Analysis by Compatible Dosage Form
    • 7.2.4. Analysis by Routes of Administration
    • 7.2.5. Analysis by Therapeutic Area
  • 7.3. Lipid Nanoparticle Technologies: List of Technology Developers
    • 7.3.1. Analysis by Year of Establishment
    • 7.3.2. Analysis by Company Size
    • 7.3.3. Analysis by Location of Headquarters
    • 7.3.4. Analysis by Company Size and Location of Headquarters
    • 7.3.5. Analysis by Business Model
    • 7.3.6. Most Active Players: Analysis by Number of Technologies

8. OTHER TYPES OF LIPIDS: SERVICE PROVIDERS LANDSCAPE

  • 8.1. Chapter Overview
  • 8.2. Other Types of Lipids: List of Service Providers
    • 8.2.1. Analysis by Year of Establishment
    • 8.2.2. Analysis by Company Size
    • 8.2.3. Analysis by Location of Headquarters
    • 8.2.4. Analysis by Company Size and Location of Headquarters
    • 8.2.5. Analysis by Location of Manufacturing Facility
    • 8.2.6. Analysis by Scale of Operation
    • 8.2.7. Analysis by Type of Lipid Manufactured
    • 8.2.8. Analysis by Scale of Operation and Type of Lipid Manufactured
    • 8.2.9. Analysis by Type of Product
    • 8.2.10. Analysis by Type of Additional Services Offered
    • 8.2.11. Analysis by Type of Product and Type of Additional Services Offered

9. COMPANY COMPETITIVENESS ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Assumptions and Key Parameters
  • 9.3. Methodology
  • 9.4. Lipid Nanoparticle Manufacturing Service Providers: Company Competitiveness Analysis
    • 9.4.1. Company Competitiveness Analysis: Small Players
    • 9.4.2. Company Competitiveness Analysis: Mid-sized Players
    • 9.4.3. Company Competitiveness Analysis: Large and Very Large Players

10. TECHNOLOGY COMPETITIVENESS ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Assumptions and Key Parameters
  • 10.3. Methodology
  • 10.4. Lipid Nanoparticle Technologies: Competitiveness Analysis
    • 10.4.1. Technology Competitiveness Analysis: Players based in North America
    • 10.4.2. Technology Competitiveness Analysis: Players based in Europe and Asia-Pacific

11. COMPANY PROFILES: SERVICE PROVIDERS OF LIPID NANOPARTICLES

  • 11.1. Chapter Overview
  • 11.2. Curia
    • 11.2.1. Company Overview
    • 11.2.2. Service Portfolio
    • 11.2.3. Recent Developments and Future Outlook
  • 11.3. Emergent BioSolutions
    • 11.3.1. Company Overview
    • 11.3.2. Service Portfolio
    • 11.3.3. Recent Developments and Future Outlook
  • 11.4. EUROAPI
    • 11.4.1. Company Overview
    • 11.4.2. Service Portfolio
    • 11.4.3. Recent Developments and Future Outlook
  • 11.5. Evonik
    • 11.5.1. Company Overview
    • 11.5.2. Service Portfolio
    • 11.5.3. Recent Developments and Future Outlook
  • 11.6. Curapath
    • 11.6.1. Company Overview
    • 11.6.2. Service Portfolio
  • 11.7. BIOVECTRA
    • 11.7.1. Company Overview
    • 11.7.2. Service Portfolio
  • 11.8. Precision NanoSystems
    • 11.8.1. Company Overview
    • 11.8.2. Service Portfolio

12. COMPANY PROFILES: LIPID NANOPARTICLE TECHNOLOGY DEVELOPERS

  • 12.1. Chapter Overview
  • 12.2. Ascendia Pharmaceuticals
    • 12.2.1. Company Overview
    • 12.2.2. Lipid Nanoparticle Technology Portfolio
    • 12.2.3. Recent Developments and Future Outlook
  • 12.3. leon-nanodrugs
    • 12.3.1. Company Overview
    • 12.3.2. Lipid Nanoparticle Technology Portfolio
    • 12.3.3. Recent Developments and Future Outlook
  • 12.4. Pantherna Therapeutics
    • 12.4.1. Company Overview
    • 12.4.2. Lipid Nanoparticle Technology Portfolio
    • 12.4.3. Recent Developments and Future Outlook
  • 12.5. TLC Biosciences
    • 12.5.1. Company Overview
    • 12.5.2. Lipid Nanoparticle Technology Portfolio
    • 12.5.3. Recent Developments and Future Outlook
  • 12.6. Acuitas Therapeutics
    • 12.6.1. Company Overview
    • 12.6.2. Lipid Nanoparticle Technology Portfolio
  • 12.7. Integrated Nanotherapeutics
    • 12.7.1. Company Overview
    • 12.7.2. Lipid Nanoparticle Technology Portfolio
  • 12.8. Matinas BioPharma
    • 12.8.1. Company Overview
    • 12.8.2. Lipid Nanoparticle Technology Portfolio

13. COMPANY PROFILES: SERVICE PROVIDERS OF OTHER TYPES OF LIPIDS

  • 13.1. Chapter Overview
  • 13.2. Avanti Polar Lipids
    • 13.2.1. Company Overview
    • 13.2.2. Service Portfolio
    • 13.2.3. Recent Developments and Future Outlook
  • 13.3. CordenPharma
    • 13.3.1. Company Overview
    • 13.3.2. Service Portfolio
    • 13.3.3. Recent Developments and Future Outlook
  • 13.4. FUJIFILM
    • 13.4.1. Company Overview
    • 13.4.2. Service Portfolio
    • 13.4.3. Recent Developments and Future Outlook
  • 13.5. Merck
    • 13.5.1. Company Overview
    • 13.5.2. Service Portfolio
    • 13.5.3. Recent Developments and Future Outlook
  • 13.6. FormuMax Scientific
    • 13.6.1. Company Overview
    • 13.6.2. Service Portfolio
  • 13.7. Creative Biolabs
    • 13.7.1. Company Overview
    • 13.7.2. Service Portfolio
  • 13.8. Fresenius Kabi
    • 13.8.1. Company Overview
    • 13.8.2. Service Portfolio

14. PARTNERSHIPS AND COLLABORATIONS

  • 14.1. Chapter Overview
  • 14.2. Partnership Models
  • 14.3. Lipid Nanoparticle Services and Technologies: List of Partnerships and Collaborations
    • 14.3.1. Analysis by Year of Partnership
    • 14.3.2. Analysis by Type of Partnership
    • 14.3.3. Analysis by Year and Type of Partnership
    • 14.3.4. Analysis by Type of Molecule
    • 14.3.5. Analysis by Therapeutic Area
    • 14.3.6. Analysis by Type of Partner
    • 14.3.7. Most Active Players: Analysis by Number of Partnerships
    • 14.3.8. Analysis by Geography
      • 14.3.8.1. Intracontinental and Intercontinental Deals
      • 14.3.8.2. International and Local Deals

15. LIKELY PARTNER ANALYSIS

  • 15.1. Chapter Overview
  • 15.2. Methodology
  • 15.3. mRNA Drug Developers: Potential Strategic Partners in North America
  • 15.4. mRNA Drug Developers: Potential Strategic Partners in Europe and Asia-Pacific

16. MAKE VERSUS BUY DECISION FRAMEWORK

  • 16.1. Chapter Overview
  • 16.2. Assumptions and Key Parameters
  • 16.3. Lipid Nanoparticle Service Providers: Make versus Buy Decision Making Framework
    • 16.3.1. Scenario 1
    • 16.3.2. Scenario 2
    • 16.3.3. Scenario 3
    • 16.3.4. Scenario 4
  • 16.4. Concluding Remarks

17. CAPACITY ANALYSIS

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. Global Installed Lipid Nanoparticle Contract Manufacturing Capacity
    • 17.3.1. Analysis by Range of Installed Capacity
    • 17.3.2. Analysis by Company Size
    • 17.3.3. Analysis by Scale of Operation
    • 17.3.4. Analysis by Location of Manufacturing Facility
      • 17.3.4.1. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in North America
      • 17.3.4.2. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in Europe
      • 17.3.4.3. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in Asia-Pacific
    • 17.3.5. Concluding Remarks

18. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 18.1. Chapter Overview
  • 18.2. Market Drivers
  • 18.3. Market Restraints
  • 18.4. Market Opportunities
  • 18.5. Market Challenges
  • 18.6. Conclusion

19. GLOBAL LIPID NANOPARTICLE MANUFACTURING MARKET

  • 19.1. Chapter Overview
  • 19.2. Assumptions and Methodology
  • 19.3. Global Lipid Nanoparticle Manufacturing Market, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 19.3.1. Scenario Analysis
      • 19.3.1.1. Conservative Scenario
      • 19.3.1.2. Optimistic Scenario
  • 19.4. Key Market Segmentations

20. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF LIPID NANOPARTICLE

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Lipid Nanoparticle
    • 20.3.1. Lipid Nanoparticle Manufacturing Market for Solid Lipid Nanoparticles, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 20.3.2. Lipid Nanoparticle Manufacturing Market for Nanostructured Lipid Carriers, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 20.4. Data Triangulation and Validation

21. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF MOLECULE DELIVERED

  • 21.1. Chapter Overview
  • 21.2. Key Assumptions and Methodology
  • 21.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Molecule Delivered
    • 21.3.1. Lipid Nanoparticle Manufacturing Market for Nucleic Acids, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 21.3.2. Lipid Nanoparticle Manufacturing Market for Small Molecules, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 21.3.3. Lipid Nanoparticle Manufacturing Market for Peptides / Proteins, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 21.3.4. Lipid Nanoparticle Manufacturing Market for Others, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 21.4. Data Triangulation and Validation

22. LIPID NANOPARTICLE MANUFACTURING MARKET, BY COMPANY SIZE

  • 22.1. Chapter Overview
  • 22.2. Key Assumptions and Methodology
  • 22.3. Lipid Nanoparticle Manufacturing Market: Distribution by Company Size
    • 22.3.1. Lipid Nanoparticle Manufacturing Market for Small Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 22.3.2. Lipid Nanoparticle Manufacturing Market for Mid-sized Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 22.3.3. Lipid Nanoparticle Manufacturing Market for Very Large and Large Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 22.4. Data Triangulation and Validation

23. LIPID NANOPARTICLE MANUFACTURING MARKET, BY THERAPEUTIC AREA

  • 23.1. Chapter Overview
  • 23.2. Key Assumptions and Methodology
  • 23.3. Lipid Nanoparticle Manufacturing Market: Distribution by Therapeutic Area
    • 23.3.1. Lipid Nanoparticle Manufacturing Market for Infectious Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 23.3.2. Lipid Nanoparticle Manufacturing Market for Oncological Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 23.3.3. Lipid Nanoparticle Manufacturing Market for Blood Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 23.3.4. Lipid Nanoparticle Manufacturing Market for Rare Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 23.3.5. Lipid Nanoparticle Manufacturing Market for Other Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 23.4. Data Triangulation and Validation

24. LIPID NANOPARTICLE MANUFACTURING MARKET, BY END-USER

  • 24.1. Chapter Overview
  • 24.2. Key Assumptions and Methodology
  • 24.3. Lipid Nanoparticle Manufacturing Market: Distribution by End-user
    • 24.3.1. Lipid Nanoparticle Manufacturing Market for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 24.3.2. Lipid Nanoparticle Manufacturing Market for Academic and Research Institutes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 24.3.3. Lipid Nanoparticle Manufacturing Market for Other End-users, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 24.4. Data Triangulation and Validation

25. LIPID NANOPARTICLE MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 25.1. Chapter Overview
  • 25.2. Key Assumptions and Methodology
  • 25.3. Lipid Nanoparticle Manufacturing Market: Distribution by Key Geographical Regions
    • 25.3.1. Lipid Nanoparticle Manufacturing Market in North America, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 25.3.2. Lipid Nanoparticle Manufacturing Market in Europe, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 25.3.3. Lipid Nanoparticle Manufacturing Market in Asia-Pacific, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 25.3.4. Lipid Nanoparticle Manufacturing Market in Rest of the World, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 25.4. Market Dynamics Assessment
    • 25.4.1. Revenue Shift Analysis
    • 25.4.2. Penetration Growth (P-G) Matrix
  • 25.5. Data Triangulation and Validation

26. LIPID NANOPARTICLE MANUFACTURING MARKET: NORTH AMERICA

  • 26.1. Lipid Nanoparticle Manufacturing Market in North America: Distribution by Type of Lipid Nanoparticle
    • 26.1.1. Lipid Nanoparticle Manufacturing Market in North America for Solid Lipid Nanoparticles, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 26.1.2. Lipid Nanoparticle Manufacturing Market in North America for Nanostructured Lipid Carriers, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 26.2. Lipid Nanoparticle Manufacturing Market in North America: Distribution by Type of Molecule Delivered
    • 26.2.1. Lipid Nanoparticle Manufacturing Market in North America for Nucleic Acids, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 26.2.2. Lipid Nanoparticle Manufacturing Market in North America for Small Molecules, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 26.2.3. Lipid Nanoparticle Manufacturing Market in North America for Peptides / Proteins, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 26.2.4. Lipid Nanoparticle Manufacturing Market in North America for Others, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 26.3. Lipid Nanoparticle Manufacturing Market in North America: Distribution by Company Size
    • 26.3.1. Lipid Nanoparticle Manufacturing Market in North America for Small Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 26.3.2. Lipid Nanoparticle Manufacturing Market in North America for Mid-sized Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 26.3.3. Lipid Nanoparticle Manufacturing Market in North America for Very Large and Large Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 26.4. Lipid Nanoparticle Manufacturing Market in North America: Distribution by Therapeutic Area
    • 26.4.1. Lipid Nanoparticle Manufacturing Market in North America for Infectious Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 26.4.2. Lipid Nanoparticle Manufacturing Market in North America for Oncological Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 26.4.3. Lipid Nanoparticle Manufacturing Market in North America for Blood Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 26.4.4. Lipid Nanoparticle Manufacturing Market in North America for Rare Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 26.4.5. Lipid Nanoparticle Manufacturing Market in North America for Other Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 26.5. Lipid Nanoparticle Manufacturing Market in North America: Distribution by End-user
    • 26.5.1. Lipid Nanoparticle Manufacturing Market in North America for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 26.5.2. Lipid Nanoparticle Manufacturing Market in North America for Academic and Research Institutes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 26.5.3. Lipid Nanoparticle Manufacturing Market in North America for Other End-users, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)

27. LIPID NANOPARTICLE MANUFACTURING MARKET: EUROPE

  • 27.1. Lipid Nanoparticle Manufacturing Market in Europe: Distribution by Type of Lipid Nanoparticle
    • 27.1.1. Lipid Nanoparticle Manufacturing Market in Europe for Solid Lipid Nanoparticles, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 27.1.2. Lipid Nanoparticle Manufacturing Market in Europe for Nanostructured Lipid Carriers, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 27.2. Lipid Nanoparticle Manufacturing Market in Europe: Distribution by Type of Molecule Delivered
    • 27.2.1. Lipid Nanoparticle Manufacturing Market in Europe for Nucleic Acids, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 27.2.2. Lipid Nanoparticle Manufacturing Market in Europe for Small Molecules, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 27.2.3. Lipid Nanoparticle Manufacturing Market in Europe for Peptides / Proteins, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 27.2.4. Lipid Nanoparticle Manufacturing Market in Europe for Others, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 27.3. Lipid Nanoparticle Manufacturing Market in Europe: Distribution by Company Size
    • 27.3.1. Lipid Nanoparticle Manufacturing Market in Europe for Small Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 27.3.2. Lipid Nanoparticle Manufacturing Market in Europe for Mid-sized Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 27.3.3. Lipid Nanoparticle Manufacturing Market in Europe for Very Large and Large Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 27.4. Lipid Nanoparticle Manufacturing Market in Europe: Distribution by Therapeutic Area
    • 27.4.1. Lipid Nanoparticle Manufacturing Market in Europe for Infectious Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 27.4.2. Lipid Nanoparticle Manufacturing Market in Europe for Oncological Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 27.4.3. Lipid Nanoparticle Manufacturing Market in Europe for Blood Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 27.4.4. Lipid Nanoparticle Manufacturing Market in Europe for Rare Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 27.4.5. Lipid Nanoparticle Manufacturing Market in Europe for Other Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 27.5. Lipid Nanoparticle Manufacturing Market in Europe: Distribution by End-user
    • 27.5.1. Lipid Nanoparticle Manufacturing Market in Europe for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 27.5.2. Lipid Nanoparticle Manufacturing Market in Europe for Academic and Research Institutes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 27.5.3. Lipid Nanoparticle Manufacturing Market in Europe for Other End-users, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)

28. LIPID NANOPARTICLE MANUFACTURING MARKET: ASIA-PACIFIC

  • 28.1. Lipid Nanoparticle Manufacturing Market in Asia-Pacific: Distribution by Type of Lipid Nanoparticle
    • 28.1.1. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Solid Lipid Nanoparticles, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 28.1.2. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Nanostructured Lipid Carriers, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 28.2. Lipid Nanoparticle Manufacturing Market in Asia-Pacific: Distribution by Type of Molecule Delivered
    • 28.2.1. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Nucleic Acids, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 28.2.2. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Small Molecules, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 28.2.3. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Peptides / Proteins, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 28.2.4. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Others, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 28.3. Lipid Nanoparticle Manufacturing Market in Asia-Pacific: Distribution by Company Size
    • 28.3.1. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Small Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 28.3.2. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Mid-sized Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 28.3.3. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Very Large and Large Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 28.4. Lipid Nanoparticle Manufacturing Market in Asia-Pacific: Distribution by Therapeutic Area
    • 28.4.1. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Infectious Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 28.4.2. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Oncological Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 28.4.3. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Blood Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 28.4.4. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Rare Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 28.4.5. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Other Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 28.5. Lipid Nanoparticle Manufacturing Market in Asia-Pacific: Distribution by End-user
    • 28.5.1. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 28.5.2. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Academic and Research Institutes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 28.5.3. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Other End-users, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)

29. LIPID NANOPARTICLE MANUFACTURING MARKET: REST OF THE WORLD

  • 29.1. Lipid Nanoparticle Manufacturing Market in Rest of the World: Distribution by Type of Lipid Nanoparticle
    • 29.1.1. Lipid Nanoparticle Manufacturing Market in Rest of the World for Solid Lipid Nanoparticles, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 29.1.2. Lipid Nanoparticle Manufacturing Market in Rest of the World for Nanostructured Lipid Carriers, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 29.2. Lipid Nanoparticle Manufacturing Market in Rest of the World: Distribution by Type of Molecule Delivered
    • 29.2.1. Lipid Nanoparticle Manufacturing Market in Rest of the World for Nucleic Acids, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 29.2.2. Lipid Nanoparticle Manufacturing Market in Rest of the World for Small Molecules, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 29.2.3. Lipid Nanoparticle Manufacturing Market in Rest of the World for Peptides / Proteins, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 29.2.4. Lipid Nanoparticle Manufacturing Market in Rest of the World for Others, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 29.3. Lipid Nanoparticle Manufacturing Market in Rest of the World: Distribution by Company Size
    • 29.3.1. Lipid Nanoparticle Manufacturing Market in Rest of the World for Small Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 29.3.2. Lipid Nanoparticle Manufacturing Market in Rest of the World for Mid-sized Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 29.3.3. Lipid Nanoparticle Manufacturing Market in Rest of the World for Very Large and Large Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 29.4. Lipid Nanoparticle Manufacturing Market in Rest of the World: Distribution by Therapeutic Area
    • 29.4.1. Lipid Nanoparticle Manufacturing Market in Rest of the World for Infectious Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 29.4.2. Lipid Nanoparticle Manufacturing Market in Rest of the World for Oncological Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 29.4.3. Lipid Nanoparticle Manufacturing Market in Rest of the World for Blood Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 29.4.4. Lipid Nanoparticle Manufacturing Market in Rest of the World for Rare Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 29.4.5. Lipid Nanoparticle Manufacturing Market in Rest of the World for Other Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 29.5. Lipid Nanoparticle Manufacturing Market in Rest of the World: Distribution by End-user
    • 29.5.1. Lipid Nanoparticle Manufacturing Market in Rest of the World for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 29.5.2. Lipid Nanoparticle Manufacturing Market in Rest of the World for Academic and Research Institutes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 29.5.3. Lipid Nanoparticle Manufacturing Market in Rest of the World for Other End-users, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)

Detailed information on Chapters 26 to 29 is available in the Excel Data Packs shared along with the report.

30. CONCLUSION

31. EXECUTIVE INSIGHTS

32. APPENDIX I: TABULATED DATA

33. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

Show more
Product Code: RA100461

List of Tables

  • Table 6.1 Lipid Nanoparticle Manufacturing: List of Service Providers
  • Table 6.2 Lipid Nanoparticle Manufacturing Service Providers: Information on Scale of Operation and Type of Molecule Delivered
  • Table 6.3 Lipid Nanoparticle Manufacturing Service Providers: Information on Therapeutic Area and Additional Services Offered
  • Table 7.1 Lipid Nanoparticle Technologies: Information on Formulation Method and Type of Molecule Delivered
  • Table 7.2 Lipid Nanoparticle Technologies: Information on Compatible Dosage Form and Routes of Administration
  • Table 7.3 Lipid Nanoparticle Technologies: Information on Therapeutic Area
  • Table 7.4 Lipid Nanoparticle Technologies: List of Technology Developers
  • Table 8.1 Other Types of Lipids: List of Service Providers
  • Table 8.2 Service Providers of Other Types of Lipids: Information on Scale of Operation and Type of Lipid Manufactured
  • Table 8.3 Service Providers of Other Types of Lipids: Information on Type of Product and Additional Services Offered
  • Table 11.1 Leading Service Providers of Lipid Nanoparticles: List of Companies Profiled
  • Table 11.2 Curia: Company Snapshot
  • Table 11.3 Curia: Manufacturing Service Portfolio for LNPs
  • Table 11.4 Curia: Recent Developments and Future Outlook
  • Table 11.5 Emergent BioSolutions: Company Snapshot
  • Table 11.6 Emergent BioSolutions: Manufacturing Service Portfolio for LNPs
  • Table 11.7 Emergent BioSolutions: Recent Developments and Future Outlook
  • Table 11.8 EUROAPI: Company Snapshot
  • Table 11.9 EUROAPI: Manufacturing Service Portfolio for LNPs
  • Table 11.10 EUROAPI: Recent Developments and Future Outlook
  • Table 11.11 Evonik: Company Snapshot
  • Table 11.12 Evonik: Manufacturing Service Portfolio for LNPs
  • Table 11.13 Evonik: Recent Developments and Future Outlook
  • Table 11.14 Curapath: Company Snapshot
  • Table 11.15 Curapath: Manufacturing Service Portfolio for LNPs
  • Table 11.16 BIOVECTRA: Company Snapshot
  • Table 11.17 BIOVECTRA: Manufacturing Service Portfolio for LNPs
  • Table 11.18 Precision NanoSystems: Company Snapshot
  • Table 11.19 Precision NanoSystems: Manufacturing Service Portfolio for LNPs
  • Table 12.1 Leading LNP Technology Providers: List of Companies Profiled
  • Table 12.2 Ascendia Pharmaceuticals: Company Snapshot
  • Table 12.3 Ascendia Pharmaceuticals: Lipid Nanoparticle Technology Portfolio
  • Table 12.4 Ascendia Pharmaceuticals: Recent Developments and Future Outlook
  • Table 12.5 leon-nanodrugs: Company Snapshot
  • Table 12.6 leon-nanodrugs: Lipid Nanoparticle Technology Portfolio
  • Table 12.7 leon-nanodrugs: Recent Developments and Future Outlook
  • Table 12.8 Pantherna Therapeutics: Company Snapshot
  • Table 12.9 Pantherna Therapeutics: Lipid Nanoparticle Technology Portfolio
  • Table 12.10 Pantherna Therapeutics: Recent Developments and Future Outlook
  • Table 12.11 TLC Biosciences: Company Snapshot
  • Table 12.12 TLC Biosciences: Lipid Nanoparticle Technology Portfolio
  • Table 12.13 TLC Biosciences: Recent Developments and Future Outlook
  • Table 12.14 Acuitas Therapeutics: Company Snapshot
  • Table 12.15 Acuitas Therapeutics: Lipid Nanoparticle Technology Portfolio
  • Table 12.16 Integrated Nanotherapeutics: Company Snapshot
  • Table 12.17 Integrated Nanotherapeutics: Lipid Nanoparticle Technology Portfolio
  • Table 12.18 Matinas BioPharma: Company Snapshot
  • Table 12.19 Matinas BioPharma: Lipid Nanoparticle Technology Portfolio
  • Table 13.1 Leading Service Providers of Other Types of Lipids: List of Companies Profiled
  • Table 13.2 Avanti Polar Lipids: Company Snapshot
  • Table 13.3 Avanti Polar Lipids: Manufacturing Service Portfolio for Other Types of Lipids
  • Table 13.4 Avanti Polar Lipids: Recent Developments and Future Outlook
  • Table 13.5 CordenPharma: Company Snapshot
  • Table 13.6 CordenPharma: Manufacturing Service Portfolio for Other Types of Lipids
  • Table 13.7 CordenPharma: Recent Developments and Future Outlook
  • Table 13.8 FUJIFILM: Company Snapshot
  • Table 13.9 FUJIFILM: Manufacturing Service Portfolio for Other Types of Lipids
  • Table 13.10 FUJIFILM: Recent Developments and Future Outlook
  • Table 13.11 Merck: Company Snapshot
  • Table 13.12 Merck: Manufacturing Service Portfolio for Other Types of Lipids
  • Table 13.13 Merck: Recent Developments and Future Outlook
  • Table 13.14 FormuMax Scientific: Company Snapshot
  • Table 13.15 FormuMax Scientific: Manufacturing Service Portfolio for Other Types of Lipids
  • Table 13.16 Creative Biolabs: Company Snapshot
  • Table 13.17 Creative Biolabs: Manufacturing Service Portfolio for Other Types of Lipids
  • Table 13.18 Fresenius Kabi: Company Snapshot
  • Table 13.19 Fresenius Kabi: Manufacturing Service Portfolio for Other Types of Lipids
  • Table 14.1 Lipid Nanoparticle Services and Technologies: List of Partnerships and Collaborations, Since 2019
  • Table 15.1 mRNA Drug Developers: Potential Strategic Partners in North America
  • Table 15.2 mRNA Drug Developers: Potential Strategic Partners in Europe and Asia-Pacific
  • Table 17.1 Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Average Capacity by Company Size (Sample Dataset)
  • Table 17.2 Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Total Capacity by Company Size (Liters)
  • Table 31.1 LIPOSOMA: Company Snapshot
  • Table 31.2 BIOVECTRA: Company Snapshot
  • Table 31.3 OZ Biosciences: Company Snapshot
  • Table 32.1 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Year of Establishment
  • Table 32.2 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Company Size
  • Table 32.3 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Location of Headquarters
  • Table 32.4 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Company Size and Location of Headquarters
  • Table 32.5 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Location of Lipid Nanoparticle Manufacturing Facility
  • Table 32.6 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Scale of Operation
  • Table 32.7 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Type of Molecule Delivered
  • Table 32.8 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Therapeutic Area
  • Table 32.9 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Type of Additional Services Offered
  • Table 32.10 Lipid Nanoparticle Technologies: Distribution by Type of Formulation Method
  • Table 32.11 Lipid Nanoparticle Technologies: Distribution by Type of Molecule Delivered
  • Table 32.12 Lipid Nanoparticle Technologies: Distribution by Compatible Dosage Form
  • Table 32.13 Lipid Nanoparticle Technologies: Distribution by Route of Administration
  • Table 32.14 Lipid Nanoparticle Technologies: Distribution by Therapeutic Area
  • Table 32.15 Lipid Nanoparticle Technology Developers: Distribution by Year of Establishment
  • Table 32.16 Lipid Nanoparticle Technology Developers: Distribution by Company Size
  • Table 32.17 Lipid Nanoparticle Technology Developers: Distribution by Location of Headquarters
  • Table 32.18 Lipid Nanoparticle Technology Developers: Distribution by Company Size and Location of Headquarters
  • Table 32.19 Lipid Nanoparticle Technology Developers: Distribution by Business Model
  • Table 32.20 Most Active Players: Distribution by Number of Technologies
  • Table 32.21 Service Providers of Other Types of Lipids: Distribution by Year of Establishment
  • Table 32.22 Service Providers of Other Types of Lipids: Distribution by Company Size
  • Table 32.23 Service Providers of Other Types of Lipids: Distribution by Location of Headquarters
  • Table 32.24 Service Providers of Other Types of Lipids: Distribution by Company Size and Location of Headquarters
  • Table 32.25 Service Providers of Other Types of Lipids: Distribution by Location of Manufacturing Facility
  • Table 32.26 Service Providers of Other Types of Lipids: Distribution by Scale of Operation
  • Table 32.27 Service Providers of Other Types of Lipids: Distribution by Type of Lipid Manufactured
  • Table 32.28 Service Providers of Other Types of Lipids: Distribution by Scale of Operation and Type of Lipid Manufactured
  • Table 32.29 Service Providers of Other Types of Lipids: Distribution by Type of Product
  • Table 32.30 Service Providers of Other Types of Lipids: Distribution by Type of Additional Services Offered
  • Table 32.31 Service Providers of Other Types of Lipids: Distribution by Type of Product and Type of Services Offered
  • Table 32.32 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2019
  • Table 32.33 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 32.34 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 32.35 Partnerships and Collaborations: Distribution by Type of Molecule
  • Table 32.36 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 32.37 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 32.38 Most Active Players: Distribution by Number of Partnerships
  • Table 32.39 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
  • Table 32.40 Partnerships and Collaborations: International and Local Deals
  • Table 32.41 Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Range of Installed Capacity (Liters)
  • Table 32.42 Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Company Size
  • Table 32.43 Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Scale of Operation
  • Table 32.44 Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Location of Manufacturing Facility
  • Table 32.45 Installed Lipid Nanoparticle Contract Manufacturing Capacity in North America
  • Table 32.46 Installed Lipid Nanoparticle Contract Manufacturing Capacity in Europe
  • Table 32.47 Installed Lipid Nanoparticle Contract Manufacturing Capacity in Asia-Pacific
  • Table 32.48 Global Lipid Nanoparticle Manufacturing Market, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 32.49 Global Lipid Nanoparticle Manufacturing Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Billion)
  • Table 32.50 Global Lipid Nanoparticle Manufacturing Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Billion)
  • Table 32.51 Lipid Nanoparticle Manufacturing Market: Distribution by Type of Lipid Nanoparticle
  • Table 32.52 Lipid Nanoparticle Manufacturing Market for Solid Lipid Nanoparticles, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 32.53 Lipid Nanoparticle Manufacturing Market for Nanostructured Lipid Carriers, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 32.54 Lipid Nanoparticle Manufacturing Market: Distribution by Type of Molecule Delivered
  • Table 32.55 Lipid Nanoparticle Manufacturing Market for Nucleic Acids, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 32.56 Lipid Nanoparticle Manufacturing Market for Small Molecules, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 32.57 Lipid Nanoparticle Manufacturing Market for Peptides / Proteins, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 32.58 Lipid Nanoparticle Manufacturing Market for Others, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 32.59 Lipid Nanoparticle Manufacturing Market: Distribution by Company Size
  • Table 32.60 Lipid Nanoparticle Manufacturing Market for Small Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 32.61 Lipid Nanoparticle Manufacturing Market for Mid-sized Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 32.62 Lipid Nanoparticle Manufacturing Market for Very Large and Large Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 32.63 Lipid Nanoparticle Manufacturing Market: Distribution by Therapeutic Area
  • Table 32.64 Lipid Nanoparticle Manufacturing Market for Infectious Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 32.65 Lipid Nanoparticle Manufacturing Market for Oncological Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 32.66 Lipid Nanoparticle Manufacturing Market for Blood Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 32.67 Lipid Nanoparticle Manufacturing Market for Rare Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 32.68 Lipid Nanoparticle Manufacturing Market for Other Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 32.69 Lipid Nanoparticle Manufacturing Market: Distribution by End-user
  • Table 32.70 Lipid Nanoparticle Manufacturing Market for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 32.71 Lipid Nanoparticle Manufacturing Market for Academic and Research Institutes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 32.72 Lipid Nanoparticle Manufacturing Market for Other End-users, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 32.73 Lipid Nanoparticle Manufacturing Market: Distribution by Key Geographical Regions
  • Table 32.74 Lipid Nanoparticle Manufacturing Market in North America, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 32.75 Lipid Nanoparticle Manufacturing Market in Europe, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 32.76 Lipid Nanoparticle Manufacturing Market in Asia-Pacific, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 32.77 Lipid Nanoparticle Manufacturing Market in Rest of the World, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 32.78 Revenue Shift Analysis: Key Geographical Regions
  • Table 32.79 Penetration Growth (P-G) Matrix: Key Geographical Regions

List of Figures

  • Figure 2.1 Research Methodology: Research Assumptions
  • Figure 2.2 Research Methodology: Project Methodology
  • Figure 2.3 Research Methodology: Forecast Methodology
  • Figure 2.4 Research Methodology: Robust Quality Control
  • Figure 2.5 Research Methodology: Key Market Segmentations
  • Figure 4.1 Executive Summary: Lipid Nanoparticle Manufacturing Service Providers Market Landscape
  • Figure 4.2 Executive Summary: Lipid Nanoparticle Technology Developers Market Landscape
  • Figure 4.3 Executive Summary: Service Providers of Other Types of Lipids Market Landscape
  • Figure 4.4 Executive Summary: Partnerships and Collaborations
  • Figure 4.5 Executive Summary: Capacity Analysis
  • Figure 4.6 Executive Summary: Market Sizing and Opportunity Analysis
  • Figure 5.1 Classification of Lipids
  • Figure 5.2 Historical Development of Lipid Nanoparticles
  • Figure 5.3 Orientation of Drug in Solid Lipid Nanoparticles and Nanostructured Lipid Carriers
  • Figure 5.4 Commonly Outsourced Lipid Nanoparticle Contract Manufacturing Services
  • Figure 6.1 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Year of Establishment
  • Figure 6.2 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Company Size
  • Figure 6.3 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Location of Headquarters
  • Figure 6.4 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Company Size and Location of Headquarters
  • Figure 6.5 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Location of Lipid Nanoparticle Manufacturing Facility
  • Figure 6.6 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Scale of Operation
  • Figure 6.7 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Type of Molecule Delivered
  • Figure 6.8 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Therapeutic Area
  • Figure 6.9 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Type of Additional Services Offered
  • Figure 7.1 Lipid Nanoparticle Technologies: Distribution by Type of Formulation Method
  • Figure 7.2 Lipid Nanoparticle Technologies: Distribution by Type of Molecule Delivered
  • Figure 7.3 Lipid Nanoparticle Technologies: Distribution by Compatible Dosage Form
  • Figure 7.4 Lipid Nanoparticle Technologies: Distribution by Route of Administration
  • Figure 7.5 Lipid Nanoparticle Technologies: Distribution by Therapeutic Area
  • Figure 7.6 Lipid Nanoparticle Technology Developers: Distribution by Year of Establishment
  • Figure 7.7 Lipid Nanoparticle Technology Developers: Distribution by Company Size
  • Figure 7.8 Lipid Nanoparticle Technology Developers: Distribution by Location of Headquarters
  • Figure 7.9 Lipid Nanoparticle Technology Developers: Distribution by Company Size and Location of Headquarters
  • Figure 7.10 Lipid Nanoparticle Technology Developers: Distribution by Business Model
  • Figure 7.11 Most Active Players: Distribution by Number of Technologies
  • Figure 8.1 Service Providers of Other Types of Lipids: Distribution by Year of Establishment
  • Figure 8.2 Service Providers of Other Types of Lipids: Distribution by Company Size
  • Figure 8.3 Service Providers of Other Types of Lipids: Distribution by Location of Headquarters
  • Figure 8.4 Service Providers of Other Types of Lipids: Distribution by Company Size and Location of Headquarters
  • Figure 8.5 Service Providers of Other Types of Lipids: Distribution by Location of Manufacturing Facility
  • Figure 8.6 Service Providers of Other Types of Lipids: Distribution by Scale of Operation
  • Figure 8.7 Service Providers of Other Types of Lipids: Distribution by Type of Lipid Manufactured
  • Figure 8.8 Service Providers of Other Types of Lipids: Distribution by Scale of Operation and Type of Lipid Manufactured
  • Figure 8.9 Service Providers of Other Types of Lipids: Distribution by Type of Product
  • Figure 8.10 Service Providers of Other Types of Lipids: Distribution by Type of Additional Services Offered
  • Figure 8.11 Service Providers of Other Types of Lipids: Distribution by Type of Product and Type of Additional Services Offered
  • Figure 9.1 Company Competitiveness Analysis: Small Players
  • Figure 9.2 Company Competitiveness Analysis: Mid-sized Players
  • Figure 9.3 Company Competitiveness Analysis: Large and Very Large Players
  • Figure 10.1 Technology Competitiveness Analysis: Lipid Nanoparticle Manufacturing Technologies Offered by Players based in North America
  • Figure 10.2 Technology Competitiveness Analysis: Lipid Nanoparticle Manufacturing Technologies Offered by Players based in Europe and Asia-Pacific
  • Figure 14.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2019
  • Figure 14.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 14.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 14.4 Partnerships and Collaborations: Distribution by Type of Molecule
  • Figure 14.5 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 14.6 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 14.7 Most Active Players: Distribution by Number of Partnerships
  • Figure 14.8 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
  • Figure 14.9 Partnerships and Collaborations: International and Local Deals
  • Figure 15.1 Spider-web Analysis: Potential Strategic Partners in North America
  • Figure 15.2 Spider-web Analysis: Potential Strategic Partners in Europe and Asia-Pacific
  • Figure 16.1 Make versus Buy Decision Making Framework
  • Figure 16.2 Make versus Buy Decision Making: Possible Scenarios
  • Figure 17.1 Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Range of Installed Capacity (Liters)
  • Figure 17.2 Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Company Size
  • Figure 17.3 Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Scale of Operation
  • Figure 17.4 Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Location of Manufacturing Facility
  • Figure 17.5 Installed Lipid Nanoparticle Contract Manufacturing Capacity in North America
  • Figure 17.6 Installed Lipid Nanoparticle Contract Manufacturing Capacity in Europe
  • Figure 17.7 Installed Lipid Nanoparticle Contract Manufacturing Capacity in Asia-Pacific
  • Figure 18.1 Market Drivers
  • Figure 18.2 Market Restraints
  • Figure 18.3 Market Opportunities
  • Figure 18.4 Market Challenges
  • Figure 19.1 Global Lipid Nanoparticle Manufacturing Market, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 19.2 Global Lipid Nanoparticle Manufacturing Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Billion)
  • Figure 19.3 Global Lipid Nanoparticle Manufacturing Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Billion)
  • Figure 20.1 Lipid Nanoparticle Manufacturing Market: Distribution by Type of Lipid Nanoparticle
  • Figure 20.2 Lipid Nanoparticle Manufacturing Market for Solid Lipid Nanoparticles, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 20.3 Lipid Nanoparticle Manufacturing Market for Nanostructured Lipid Carriers, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 21.1 Lipid Nanoparticle Manufacturing Market: Distribution by Type of Molecule Delivered
  • Figure 21.2 Lipid Nanoparticle Manufacturing Market for Nucleic Acids, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 21.3 Lipid Nanoparticle Manufacturing Market for Small Molecules, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 21.4 Lipid Nanoparticle Manufacturing Market for Peptides / Proteins, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 21.5 Lipid Nanoparticle Manufacturing Market for Others, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 22.1 Lipid Nanoparticle Manufacturing Market: Distribution by Company Size
  • Figure 22.2 Lipid Nanoparticle Manufacturing Market for Small Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 22.3 Lipid Nanoparticle Manufacturing Market for Mid-sized Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 22.4 Lipid Nanoparticle Manufacturing Market for Very Large and Large Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 23.1 Lipid Nanoparticle Manufacturing Market: Distribution by Therapeutic Area
  • Figure 23.2 Lipid Nanoparticle Manufacturing Market for Infectious Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 23.3 Lipid Nanoparticle Manufacturing Market for Oncological Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 23.4 Lipid Nanoparticle Manufacturing Market for Blood Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 23.5 Lipid Nanoparticle Manufacturing Market for Rare Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 23.6 Lipid Nanoparticle Manufacturing Market for Other Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 24.1 Lipid Nanoparticle Manufacturing Market: Distribution by End-user
  • Figure 24.2 Lipid Nanoparticle Manufacturing Market for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 24.3 Lipid Nanoparticle Manufacturing Market for Academic and Research Institutes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 24.4 Lipid Nanoparticle Manufacturing Market for Other End-users, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 25.1 Lipid Nanoparticle Manufacturing Market: Distribution by Key Geographical Regions
  • Figure 25.2 Lipid Nanoparticle Manufacturing Market in North America, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 25.3 Lipid Nanoparticle Manufacturing Market in Europe, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 25.4 Lipid Nanoparticle Manufacturing Market in Asia-Pacific, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 25.5 Lipid Nanoparticle Manufacturing Market in Rest of the World, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 25.6 Revenue Shift Analysis: Key Geographical Regions
  • Figure 25.7 Penetration Growth (P-G) Matrix: Key Geographical Regions
  • Figure 30.1 Concluding Remarks: Lipid Nanoparticle Manufacturing Service Providers Market Landscape
  • Figure 30.2 Concluding Remarks: Lipid Nanoparticle Technology Developers Market Landscape
  • Figure 30.3 Concluding Remarks: Service Providers of Other Types of Lipids Market Landscape
  • Figure 30.4 Concluding Remarks: Partnerships and Collaborations
  • Figure 30.5 Concluding Remarks: Capacity Analysis
  • Figure 30.6 Concluding Remarks: Market Forecast and Opportunity Analysis (I/II)
  • Figure 30.7 Concluding Remarks: Market Forecast and Opportunity Analysis (II/II)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!